This case study details how Sol-Gel Technologies partnered with Citeline to boost enrollment for a clinical trial targeting Gorlin syndrome — an extremely rare and debilitating skin condition affecting roughly 1 in 31,000 people. With enrollment falling behind schedule, Citeline launched a rapid HCP Awareness email campaign across seven countries to drive awareness and engagement with the Sol-Gel team.
